Imatinib Viatris

Imatinib, the active ingredient in Imatinib Viatris, is a tyrosine kinase inhibitor presented as a tablet for oral use. It is indicated for the treatment of chronic myeloid leukemia, Philadelphia chromosome‑positive acute lymphoblastic leukemia, and gastrointestinal stromal tumor in adult patients.

GNH USA supplies Imatinib Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The product meets European Union quality standards and is distributed to clinical sites in North America, Europe and Asia globally.

Imatinib acts on specific tyrosine kinase‑driven malignancies, providing targeted therapy for several hematologic and solid tumors.

- Chronic myeloid leukemia (CML): reduces leukemic cell proliferation and achieves durable molecular remission. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): induces remission by blocking BCR‑ABL signaling. - Gastrointestinal stromal tumor (GIST): inhibits KIT‑driven tumor growth, leading to disease control.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Edema: peripheral swelling, often in the ankles. - Muscle cramps: intermittent skeletal muscle discomfort. - Fatigue: generalized tiredness.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver failure. - Severe neutropenia: marked reduction in neutrophil count increasing infection risk. - Cardiac failure: reduced left‑ventricular ejection fraction. - Pulmonary hypertension: elevated pressure in pulmonary arteries.

Before initiating therapy, clinicians should assess baseline organ function and monitor patients regularly.

- Monitor blood counts: perform complete blood count at baseline and periodically. - Assess liver function: check hepatic enzymes before and during treatment. - Evaluate cardiac status: perform echocardiogram if pre‑existing heart disease. - Avoid in patients with known hypersensitivity to imatinib or its excipients. - Store at below 25°C: keep in the original pack, protect from moisture.

Imatinib may interact with several concomitant medicines, requiring dose adjustments or monitoring.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase imatinib plasma levels. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic exposure. - Warfarin: concurrent use can enhance anticoagulant effect and raise INR.

Moderate Interactions (Monitor Closely): - Proton‑pump inhibitors: may modestly affect gastric pH and absorption. - Diuretics: can exacerbate electrolyte disturbances when combined with imatinib‑related fluid retention. - Other myelosuppressive agents: increase risk of cytopenias and require closer hematologic monitoring.